A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver Disease.

Boyer-Diaz, Zoe; Domingo, Joan Carles; De Gregorio, Estefanía; Manicardi, Nicolò; Aristu-Zabalza, Peio; Cordobilla, Begoña; Abad-Jordà, Laia; Ortega-Ribera, Martí; Fernández-Iglesias, Anabel; Marí, Montserrat; Bosch, Jaime; Gracia-Sancho, Jordi (2019). A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver Disease. Nutrients, 11(10) Molecular Diversity Preservation International MDPI 10.3390/nu11102358

[img]
Preview
Text
nutrients-11-02358.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (3MB) | Preview

Inflammation and oxidative stress play a key role in the pathophysiology of advanced chronic liver disease (ACLD) and portal hypertension (PH). Considering the current lack of effective treatments, we evaluated an anti-inflammatory and antioxidant nutraceutical rich in docosahexaenoic acid (DHA) as a possible therapy for ACLD. We investigated the effects of two-week DHA supplementation (500 mg/kg) on hepatic fatty acids, PH, oxidative stress, inflammation, and hepatic stellate cell (HSC) phenotype in rats with ACLD. Additionally, the effects of DHA were evaluated in murine macrophages and human HSC. In contrast to vehicle-treated animals, cirrhotic rats receiving DHA reestablished a healthy hepatic fatty acid profile, which was associated with an improvement in PH. The mechanisms underlying this hemodynamic improvement included a reduction in oxidative stress and inflammation, as well as a marked HSC deactivation, confirmed in human HSC. Experiments with cultured macrophages showed that treatment with DHA protects against pro-inflammatory insults. The present preclinical study demonstrates that a nutraceutical rich in DHA significantly improves PH in chronic liver disease mainly by suppressing inflammation and oxidative stress-driven HSC activation, encouraging its evaluation as a new treatment for PH and cirrhosis.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie

UniBE Contributor:

Bosch, Jaime and Gracia Sancho, Jorge Sergio

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2072-6643

Publisher:

Molecular Diversity Preservation International MDPI

Language:

English

Submitter:

Thi Thao Anh Pham

Date Deposited:

17 Jan 2020 14:13

Last Modified:

28 Nov 2020 02:30

Publisher DOI:

10.3390/nu11102358

PubMed ID:

31623374

Uncontrolled Keywords:

DHA hepatic hemodynamics liver cirrhosis liver fibrosis omega-3

BORIS DOI:

10.7892/boris.137285

URI:

https://boris.unibe.ch/id/eprint/137285

Actions (login required)

Edit item Edit item
Provide Feedback